VIR - BREAKOUT IN THE HORIZON - POSSIBLY IN JAN/FEB 2022
The VIR weekly chart shows an obvious resemblance between Phase 1 and Phase 2, so we can expect a breakout to $80-90 zone on good news, for example Q4 Earning report with Covid treatmengt Sotrovimab sales worldwide or good trial readouts from their developing products, when the Phase 2 completed.
Note: VIR share price is heavily undervalued, the fair share value is $46. The company has good recent ERs. They have 1 billion in cash, no debt.
Buy zone: $30-35, enter now after the last fall on the news on Pfizer's pill, but it will go through ups and downs before the possible spike or wait until Waves F, G completed (which is safer but you can miss the spike if you enter too late)
Price Target: $80-85 in three months
My ideas can be 100% wrong, please do your own DDs before entering a position with VIR or any other stocks
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Note: VIR share price is heavily undervalued, the fair share value is $46. The company has good recent ERs. They have 1 billion in cash, no debt.
Buy zone: $30-35, enter now after the last fall on the news on Pfizer's pill, but it will go through ups and downs before the possible spike or wait until Waves F, G completed (which is safer but you can miss the spike if you enter too late)
Price Target: $80-85 in three months
My ideas can be 100% wrong, please do your own DDs before entering a position with VIR or any other stocks
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Comment:
The breakout has started earlier than I expected due to the fear of the Omicron variant and the hope that Sotrovimab will be effective against that. December looks extremely bullish for this trade. HC Wainwright & Co. has just reiterated coverage of Vir Biotechnology with a rating of Buy and set a new price target of $200.00 from $135.00 previously
www.reuters.com/worl...ody-drug-2021-11-17/